United Kingdom
Biofortuna is a biotechnology company headquartered in the United Kingdom. Founded in 2008, the company specializes in development and contract manufacturing for the global in vitro diagnostic and point of care testing sectors.
With a strong focus on forming unique partnerships with innovative healthcare and life science companies, Biofortuna aims to enhance health and wellbeing worldwide. The company's broad range of services caters to diagnostic companies, food safety experts, and life science specialists, with a commitment to long-term partnerships and value-driven collaboration.
Biofortuna operates from state-of-the-art, purpose-built premises and holds ISO 13485 certification, ISO 17025 accreditation, and FDA registration. The company has a proven track record in the development and large-scale manufacture of PCR and LAMP molecular assays and immunoassays.
In April 2012, Biofortuna secured a significant £2.10M Venture Round investment, attracting funding from notable investors including Foresight Group, Merseyside Special Investment Fund, and Catapult Venture Managers.
